The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DVAX | -8.17% | +169.88% | +21.95% | -88% |
| S&P | +13% | +86.41% | +13.26% | +490% |
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
One pundit believes the share price could more than double.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $94.88M | 17.7% |
| Gross Profit | $80.47M | 19.1% |
| Gross Margin | 84.82% | 1.0% |
| Market Cap | $1.16B | -20.2% |
| Market Cap / Employee | $2.88M | 0.0% |
| Employees | 405 | -0.7% |
| Net Income | $26.93M | 53.0% |
| EBITDA | $23.37M | 92.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $160.25M | 34.3% |
| Accounts Receivable | $72.36M | -1.3% |
| Inventory | 73.3 | 17.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $244.95M | -2.1% |
| Short Term Debt | $44.27M | 900.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.32% | -6.3% |
| Return On Invested Capital | 5.03% | 14.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $32.59M | 79.9% |
| Operating Free Cash Flow | $33.83M | 73.8% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 229.81 | 102.74 | 85.50 | 73.10 | - |
| Price to Book | 2.46 | 2.73 | 2.31 | 2.36 | 9.71% |
| Price to Sales | 7.05 | 5.50 | 4.34 | 4.10 | -37.99% |
| Price to Tangible Book Value | 2.47 | 2.74 | 2.32 | 2.37 | 9.86% |
| Price to Free Cash Flow TTM | 32.48 | 29.98 | 20.77 | 16.83 | -77.88% |
| Enterprise Value to EBITDA | 3404.72 | -57.81 | 63.66 | 42.65 | -57.40% |
| Free Cash Flow Yield | 3.1% | 3.3% | 4.8% | 5.9% | 352.11% |
| Return on Equity | 4.5% | -10.5% | -9.3% | -7.1% | -324.28% |
| Total Debt | $254.42M | $290.11M | $289.57M | $289.22M | 13.60% |
No podcast episodes available.
DVAX earnings call for the period ending December 31, 2024.
DVAX earnings call for the period ending September 30, 2024.
DVAX earnings call for the period ending June 30, 2024.
DVAX earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
